Pharmacokinetic interaction between HCV protease inhibitor boceprevir and methadone or buprenorphine in subjects on stable maintenance therapy
Ellen G. J. Hulskotte(MSD K.K. (Japan)), Joan R. Butterton(Merck & Co., Inc., Rahway, NJ, USA (United States)), R. Douglas Bruce, Edward O’Mara(Merck & Co., Inc., Rahway, NJ, USA (United States)), Hwa-ping Feng(Merck & Co., Inc., Rahway, NJ, USA (United States)), John A. Wagner(Merck & Co., Inc., Rahway, NJ, USA (United States)), Lynn R. Webster(Adherent Technologies (United States)), Wen Lin(Merck & Co., Inc., Rahway, NJ, USA (United States)), Feng Xuan(Merck & Co., Inc., Rahway, NJ, USA (United States))
Cited by 21
Related Papers
Predicting Aberrant Behaviors in Opioid-Treated Patients: Preliminary Validation of the Opioid Risk Tool
|Pain Medicine|2005|1.1k
Estimating GFR Using Serum Cystatin C Alone and in Combination With Serum Creatinine: A Pooled Analysis of 3,418 Individuals With CKD
|American Journal of Kidney Diseases|2008|1k
Risk Factors for Opioid-Use Disorder and Overdose
|Anesthesia & Analgesia|2017|504
Naloxegol for Opioid-Induced Constipation in Patients with Noncancer Pain
|New England Journal of Medicine|2014|331
Sleep-Disordered Breathing and Chronic Opioid Therapy
|Pain Medicine|2007|309